The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation

NCT06504186 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

B-ALL

Interventions

DRUG: Blinatumomab

Sponsor

Institute of Hematology & Blood Diseases Hospital, China